MBX Latest Press Releases

-- November 5, 2026 --

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market Globe Newswire 9:20 AM

-- October 13, 2026 --

MBX Biosciences to Participate in Upcoming November Investor Conferences Globe Newswire 8:00 AM

-- September 9, 2026 --

MBX Biosciences to Participate in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- September 8, 2026 --

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer Globe Newswire 8:00 AM

-- August 27, 2026 --

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Globe Newswire 8:00 AM

-- August 6, 2026 --

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 8:00 AM

-- July 15, 2026 --

Attovia Therapeutics Appoints John W. Smither to Board of Directors Globe Newswire 8:30 AM

-- July 13, 2026 --

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth Globe Newswire 4:15 PM

-- June 12, 2026 --

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes